Report of Foreign Issuer (6-k)
December 12 2017 - 6:06AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
December 11, 2017
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X]
|
Form 40-F [ ]
|
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
Novo Nordisk A/S – Share
repurchase programme
Bagsværd, Denmark, 11 December 2017
– On 1 November 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No.
596/2014 of the European Parliament and Council of 16 April 2014 (MAR), also referred to as the Safe Harbour rules. This programme
is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 2 February
2017.
Under the programme initiated 1 November 2017,
Novo Nordisk will repurchase B shares for an amount up to DKK 4.8 billion in the period from 1 November 2017 to 30 January 2018.
Since the announcement as of 4 December 2017,
the following transactions have been made under the programme:
|
|
|
Number of
B shares
|
|
|
|
Average
purchase price
|
|
|
|
Transaction
value, DKK
|
|
Accumulated, last announcement
|
|
|
6,035,000
|
|
|
|
|
|
|
|
1,939,154,255
|
|
4 December 2017
|
|
|
270,000
|
|
|
|
325.95
|
|
|
|
88,006,336
|
|
5 December 2017
|
|
|
265,000
|
|
|
|
321.03
|
|
|
|
85,071,953
|
|
6 December 2017
|
|
|
250,000
|
|
|
|
329.94
|
|
|
|
82,483,802
|
|
7 December 2017
|
|
|
250,000
|
|
|
|
327.10
|
|
|
|
81,774,741
|
|
8 December 2017
|
|
|
250,000
|
|
|
|
325.68
|
|
|
|
81,419,550
|
|
Accumulated under the programme
|
|
|
7,320,000
|
|
|
|
|
|
|
|
2,357,910,636
|
|
The details for each transaction made under the share repurchase
programme are published on
novonordisk.com.
Page 2 of 2
With the transactions stated above, Novo Nordisk
owns a total of 53,311,054 B shares of DKK 0.20, corresponding to 2.1% of the share capital, as treasury shares. The total amount
of A and B shares in the company is 2,500,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for
an amount up to DKK 17 billion during a 12-month period beginning 2 February 2017. As of 8 December 2017, Novo Nordisk has repurchased
a total of 52,211,831 B shares equal to a transaction value of DKK 14,557,881,664.
Novo Nordisk is a global healthcare company with more than
90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable
us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark,
Novo Nordisk employs approximately 41,700 people in 77 countries and markets its products in more than 165 countries. Novo Nordisk's
B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information,
visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube
Further information
Media:
|
Anne Margrethe Hauge
|
+45 4442 3450
|
amhg@novonordisk.com
|
Ken Inchausti (US)
|
+1 609 786 8316
|
kiau@novonordisk.com
|
|
|
|
Investors
:
|
Peter Hugreffe Ankersen
|
+45 3075 9085
|
phak@novonordisk.com
|
Hanna Ögren
|
+45 3079 8519
|
haoe@novonordisk.com
|
Anders Mikkelsen
|
+45 3079 4461
|
armk@novonordisk.com
|
Christina Kjær
|
+45 3079 3009
|
cnje@novonordisk.com
|
Kasper Veje (US)
|
+1 609 235 8567
|
kpvj@novonordisk.com
|
Novo Nordisk A/S
Investor Relations
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
|
|
|
Company announcement No 91 / 2017
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: December 11, 2017
|
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer
|
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Sep 2023 to Sep 2024